Pages that link to "Q24632704"
Jump to navigation
Jump to search
The following pages link to Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma (Q24632704):
Displaying 50 items.
- Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13) (Q21134099) (← links)
- Genetics and genomics of radiotherapy toxicity: towards prediction (Q21183971) (← links)
- Risk factors for subsequent endocrine-related cancer in childhood cancer survivors (Q26745707) (← links)
- HZE Radiation Non-Targeted Effects on the Microenvironment That Mediate Mammary Carcinogenesis (Q26750868) (← links)
- Personalized Cancer Risk Assessments for Space Radiation Exposures (Q26768260) (← links)
- Second malignant neoplasms and cardiovascular disease following radiotherapy (Q26864522) (← links)
- Solid tumor second primary neoplasms: who is at risk, what can we do? (Q27026266) (← links)
- The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance (Q28074414) (← links)
- A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus (Q28943487) (← links)
- Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine. (Q30248284) (← links)
- Radiogenomics: radiobiology enters the era of big data and team science (Q30833608) (← links)
- Triple jeopardy for Hodgkin lymphoma survivors? (Q33917146) (← links)
- Limited evidence for parent-of-origin effects in inflammatory bowel disease associated loci (Q34428615) (← links)
- Current knowledge and future research directions in treatment-related second primary malignancies (Q34604460) (← links)
- Minimizing second cancer risk following radiotherapy: current perspectives (Q34757180) (← links)
- Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors (Q35117677) (← links)
- Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors (Q35327266) (← links)
- c-MYC is a radiosensitive locus in human breast cells (Q35348121) (← links)
- Molecular pathogenesis of secondary acute promyelocytic leukemia (Q35560260) (← links)
- Subsequent malignant neoplasms after hematopoietic cell transplantation (Q35678455) (← links)
- Secondary Malignancies Following Treatment for Hodgkin's Lymphoma in Childhood and Adolescence (Q35682335) (← links)
- Predicting outcomes in radiation oncology--multifactorial decision support systems (Q36014711) (← links)
- Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research (Q36535678) (← links)
- STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics (Q36672778) (← links)
- Secondary Neoplasms in Children with Hodgkin's Lymphoma Receiving C-MOPP and Radiotherapy: Presentation of Four Cases (Q36722784) (← links)
- Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk (Q36736612) (← links)
- Does radiation-induced c-MYC amplification initiate breast oncogenesis? (Q36836096) (← links)
- Clinical Guidelines for the Care of Childhood Cancer Survivors (Q37055826) (← links)
- Childhood cancer survivorship research in minority populations: A position paper from the Childhood Cancer Survivor Study. (Q37116007) (← links)
- Childhood cancer survivorship: an update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects (Q37167767) (← links)
- Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms (Q37207597) (← links)
- Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis (Q37219761) (← links)
- Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy (Q37457332) (← links)
- A population-based comparison of second primary cancers in Germany and Sweden between 1997 and 2006: clinical implications and etiologic aspects (Q37482598) (← links)
- Genetic predisposition to radiation-related cancer and potential implications for risk assessment (Q37564554) (← links)
- Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy (Q37624254) (← links)
- The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment (Q37727786) (← links)
- Neurocognitive function after radiotherapy for paediatric brain tumours (Q38042263) (← links)
- Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma (Q38068839) (← links)
- Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors (Q38093037) (← links)
- Radiogenomics: the search for genetic predictors of radiotherapy response (Q38294605) (← links)
- Prognostic Biomarkers for Hodgkin Lymphoma (Q38588503) (← links)
- Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. (Q38775871) (← links)
- Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History (Q38850144) (← links)
- Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of follow-up (Q39727079) (← links)
- Increased risk of second malignant neoplasms in adolescents and young adults with cancer. (Q40461439) (← links)
- TNFSF10/TRAIL regulates human T4 effector memory lymphocyte radiosensitivity and predicts radiation-induced acute and subacute dermatitis (Q40996284) (← links)
- HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells (Q41527488) (← links)
- Radiation-Induced Malignancies Making Radiotherapy a "Two-Edged Sword": A Review of Literature (Q41835022) (← links)
- Genome-wide association study of chronic hepatitis B virus infection reveals a novel candidate risk allele on 11q22.3. (Q42267178) (← links)